AstraZeneca, FibroGen Plan New Roxadustat Filings, But CV Data Confuse Investors

Confusion over top-line pooled cardiovascular Phase III safety data on anemia therapy roxadustat caused shares in AstraZeneca and FibroGen to slide on 9 May, but analysts later said the negative reaction was overdone.